menu
    • menu
    [{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Iontas","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FairJourney Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"FairJourney Biologics \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"FairJourney Biologics \/ FairJourney Biologics"},{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Iontas","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FairJourney Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"FairJourney Biologics \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"FairJourney Biologics \/ FairJourney Biologics"},{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Iontas","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FairJourney Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"FairJourney Biologics \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"FairJourney Biologics \/ FairJourney Biologics"},{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"FairJourney Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FairJourney Biologics \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"FairJourney Biologics \/ Argenx"}]

    Find Clinical Drug Pipeline Developments & Deals by FairJourney Biologics

    Menu

    FairJourney Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FairJourney Biologics Enters Next-Generation Antibody Discovery Collaboration with Argenx

                            Details : FJB and IONTAS will provide argenx with access to IONTAS’ novel mammalian display technology, which can generate abundant therapeutic antibody leads, selecting for key attributes that may address the novel targets or pathways that argenx is exploring.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 04, 2021

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Recipient : Iontas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies

                            Details : The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified potent neutralizing antibodies with distinct mechanisms of action.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Recipient : Iontas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Iontas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IONTAS and FairJourney Biologics Discover SARS-CoV2 Neutralizing Antibodies with Picomolar Potency

                            Details : The newly-identified panel of antibodies have been shown to block infection at doses as low as 20pM in pseudoviral assays and 100pM in live coronavirus assays, surpassing or matching the best antibodies reported.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Iontas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed

                            FairJourney Biologics

                            Portugal arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Iontas

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            FairJourney Biologics and Iontas Announce Partnership in Search for SARS-CoV-2 Treatment

                            Details : The combination will enable the newly created partnership to isolate highly specific, neutralizing SARS-CoV-2 antibodies displaying high affinity and preferential biophysical characteristics.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 16, 2020

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Iontas

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth